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Glioma is a rare brain tumour with a very poor prognosis and the search for modifiable factors is intense. We reviewed the
literature concerning risk factors for glioma obtained in case–control designed epidemiological studies in order to discuss the
influence of this methodology on the observed results. When reviewing the association between three exposures, medical
radiation, exogenous hormone use and allergy, we critically appraised the evidence from both case–control and cohort studies.
For medical radiation and hormone replacement therapy (HRT), questionnaire-based case–control studies appeared to show an
inverse association, whereas nested case–control and cohort studies showed no association. For allergies, the inverse association
was observed irrespective of study design. We recommend that the questionnaire-based case–control design be placed lower in
the hierarchy of studies for establishing cause-and-effect for diseases such as glioma. We suggest that a state-of-the-art case–
control study should, as a minimum, be accompanied by extensive validation of the exposure assessment methods and the
representativeness of the study sample with regard to the exposures of interest. Otherwise, such studies cannot be regarded as
‘hypothesis testing’ but only ‘hypothesis generating’. We consider that this holds true for all questionnaire-based case–control
studies on cancer and other chronic diseases, although perhaps not to the same extent for each exposure–outcome combination.
Studies of the aetiology of glioma, the commonest malignant brain
tumour, with a very poor prognosis, are urgently needed,
specifically to identify modifiable risk factors. The main reason
that researchers have used the case–control design as the model of
choice for epidemiological studies on the causes of glioma is that it
a rare cancer, with an incidence of 4 per 100 000 people (World
Standard Population) in Denmark, an incidence typical for a high-
income country (Christensen et al, 2003). Furthermore, the design
limits the time required to obtain data, the cost is lower than that
of more time-consuming designs and a wide range of suspected
risk factors can be examined in the same study. In case–control
studies, questionnaire data, blood samples and tissue specimens
can be obtained from both cases and controls, thereby allowing
analysis of both environmental and genetic factors and their
interactions.
In questionnaire-based case–control studies, it is anticipated
that cases can recall past events with sufficient accuracy. This a
priori assumption is somewhat naive in the case of glioma in view
of the well-known clinical presentation of the disease. The cancer
itself, surgery, radiotherapy, chemotherapy and any combination of
treatment may strongly influence the overall cognitive capacity of
patients. Some have overt cognitive deficits and may therefore be
unable to remember past events or have selective recall.
Researchers may have to interview a proxy of the patient, as is
often the case in case–control studies of risk factors for glioma.
Finding suitable controls presents another challenge. They must
be from the same study population as the cases, as the source may
influence reported exposures, and selection may be introduced
when potential controls decide whether to participate in a study. If
these sources of error are systematically different in terms of the
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Table 1. Overview of reports by study design on three potential risk factors for glioma: medical radiation, exogenous hormone
use and allergic disease
First author, country, year, study design
Case–control study
N glioma cases/N controls; % proxy in case group;
% control participation
Cohort study
N participants; N glioma cases; mean follow-up
Definition of exposure and risk
estimates
Medical radiation
Preston-Martin, USA, 1989, case–control 202/202 (Male)
Not provided
Not provided
Full-mouth X-rayo25 years age: every 2–5
years, OR, 1.6 (0.7–3.6); once a year, OR, 3.0
(0.6–14.9); P-value for trend 0.04
Neuberger, USA, 1991, case–control 7/14
100% (Cases and controls deceased)
100%
Dental X-rays, OR, 10.66 (1.95–58.25)
Schlehofer, Germany, 1992, case–control 115/418
o1%
72%
Any X-rays of head and neck OR, 1.21 (0.6–
2.3)
Ryan, Australia, 1992, case–control 110/419
Not provided
63%
Ever dental X-rays, OR, 0.42 (0.24–0.76)
Full-mouth X-rays, OR, 1.98 (0.72–5.39)
Zampieri, Italy, 1994, case–control 195/195 (Hospital controls)
100%
100%
Any diagnostic Xx-ray, OR, 0.4 (0.1–1.0)
Ruder, USA, 2006, case–control 798/1175
Not provided
70% of 1670 eligible
Ever full-mouth dental X-rays, OR 0. 75,
(0.61–0.92)
Blettner, Germany, 2007, case–control 366/732
11%
63% (80% for cases)
Any medical ionising radiation, OR, 0.62
(0.47–0.82)
Davis, USA, 2011, case–control 205/333
Not provided
Not provided
1 or more yearly dental X-rays, OR, 0.60
(0.21–1.73)
3 or more full-mouth X-ray, OR, 0.70 (0.40–
1.21)
Exogenous hormones
Huang, USA, 2004, case–control 341/527
43%
72%
Ever OC, OR, 0.83 (0.58–1.20)
Ever HRT, OR, 0.73 (0.49–1.10)
Hatch, USA, 2005, case–control 212/436 Hospital controls
16%
89%
Ever OC, OR, 0.66 (0.44–1.00)
Ever HRT, OR, 0.66 (0.41–1.09)
Wigertz, Sweden, 2006, Case–Control 132/323
Proxies excluded
Not provided
Ever OC, OR, 0.8 (0.5–1.4)
Ever HRT, OR, 0.9 (0.4–1.7)
Silvera, Canada, 2006, cohort 89,835 Women
120 Cases of glioma
Mean follow-up 16.4 years
Ever OC, RR, 1.01 (0.68–1.52)
Ever HRT, RR, 0.92 (0.55–1.56)
Benson, UK, 2008, cohort 1 249 670 Women
646 Glioma cases
Mean follow-up 6.3 years
OC o5 years, RR, 0.88 (0.72–1.09)
OC 45 years, RR, 0.88 (0.72–1.06)
Felini, USA, 2009, case–control 619/650
79%
37%
Ever OC, OR, 0.62 (0.47–0.82)
Ever HRT, OR, 0.57 (0.41–0.79)
Michaud, Europe, 2010, cohort 276 212 Women
193 Glioma cases
Mean follow-up 8.4 years
Former OC, RR, 0.84 (0.61–1.18)
Current OC, RR, 1.23 (0.53–2.83)
Former HRT, RR, 0.93 (0.55–1.56)
Current HRT, RR, 0.76 (0.49–1.19)
Kabat, USA, 2011, cohort 3 Twin cohorts
I: N¼14 535
37 Glioma cases
Median follow-up 26 years
II: N¼29 573
42 glioma cases
Median follow-up 26 years
Combination of I–II N¼52 067
68 Glioma cases
Median follow-up 20 years
Ever HRT, HR, 0.99 (0.63–1.56)
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Table 1. ( Continued )
First author, country, year, study design
Case–control study
N glioma cases/N controls; % proxy in case group;
% control participation
Cohort study
N participants; N glioma cases; mean follow-up
Definition of exposure and risk
estimates
Andersen, Denmark, 2013, case–control 411/2587
0% (Nested in cohort)
100% (Nested in cohort)
Ever HRT, 0.9 (0.8–1.1)
Anic, USA, 2014, case–control 507/141 Friend controls/554 community controls
2.6%
Not provided
Ever OC, OR, 0.77 (0.57–1.03)
Benson, UK, 2015, case–control 689/13,997
Not provided
Not provided
Ever (1þ prescription) HRT, 1.14 (0.93–1.40)
Allergy
Cicuttini, Australia, 1997, case–control 416/422
44%
65%
Asthma: 0.8 (0.5–1.2)
Eczema: 0.9 (0.5–1.4)
Schlehofer, Australia, Canada, France,
Germany, Sweden, 1999, case–control
1178/1987
26%
Not provided
Any allergy, OR, 0.59 (0.49–0.71)
Wiemels, USA, 2002, case–control 405/402
34%
74%
Any allergy, OR, 0.47 (0.33–0.67)
Excluding proxy cases, OR 0.65 (0.43–0.97)
Brenner, USA, 2002, case–control 489/799 hospital controls
24%
86%
Any allergy, OR, 0.67 (0.52–0.86)
Schwartzbaum, Sweden, 2003, cohort 3 Twin cohorts
I: N¼14 535
37 Glioma cases
Median follow-up 26 years
II: N¼29 573
42 Glioma cases
Median follow-up 26 years
Combination of I–II N¼52 067
68 Glioma cases
Median follow-up 20 years
Any allergy, self-report
Cohort I: HR, 0.45 (0.19–1.07)
Cohort II: HR, 1.09 (0.48–2.48)
Discharge with immune-related diseases
(asthma, croup, eczema, psoriasis and
autoimmune disease)
Cohort Iþ II: HR, 0.46 (0.14–1.48)
Wiemels, USA, 2004, case–control 226/289
Not provided
Not provided
Serum IgE level elevated, OR, 0.37 (0.22–
0.64)
Self-reported allergies
1–3 Allergies, OR 0.69 (0.42–1.1)
4þ Allergies, OR, 0.50 (0.28–0.88)
Schoemaker, UK, 2006, case–control 965/1716
Not provided
45%
Any allergy, OR, 0.63 (0.53–0.76)
Wigertz, Denmark, Norway, Finland, Sweden,
UK, 2007, case–control
1527/3309
13%
50%
Any allergy, OR, 0.70 (0.61–0.80)
Scheurer, USA, 2008, case–control 325/600
4%
53%
Allergy or asthma, OR, 0.34 (0.23–0.51)
Antihistamines, OR, 1.37 (0.87–2.14)
Among allergic persons, antihistamine use
OR, 2.54 (1.28–5.03)
Il’yasova, USA, 2009, case–control 388/(80 Siblings/191 friends/177 clinic based)
Not provided
83%
Any allergy
(sibling controls) OR, 0.53 (0.15–1.84)
(friend controls) OR, 0.54 (0.28–1.07)
(Clinic-based controls) OR, 0.34 (0.23–0.50)
Berg-Beckhoff, Germany, 2009, case–control 366/1535
3.2%
63%
Any allergy, OR, 0.92 (0.70–1.22)
Wiemels, USA, 2009, case–control 535/565
24%
92%
Any allergy, OR, 0.50 (0.36–0.70)
McCarthy, US, 2011, case–control 419/612 (Hospital controls)
Not provided
71%
Any allergy, OR, 0.60 (0.46–0.79)
Any antihistamine use, OR, 0.76 (0.59–0.99)
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exposures of interest from those in the case group, bias will be
present. Bias can be addressed partly with statistical tools; however,
they require either some idea of the nature and magnitude of bias
from validation studies or assumptions about potential bias in
sensitivity analyses. Neither necessarily leads to a satisfactory
outcome, especially if the results differ substantially according to
the assumptions. Despite these potentially serious limitations of
case–control studies, there has been no in-depth debate about
situations in which questionnaire-based case–control studies are
unlikely to provide reliable results. In some narrative syntheses and
meta-analytical reviews, the results of such studies contribute
equally to the evidence base, even though application of study
quality indicators is recommended when summarising evidence. It
is therefore important to consider the level of evidence from case–
control studies based solely on differential reconstruction of past
exposures as compared with that from prospective studies for
investigating glioma, when reconstruction of exposure is hampered
by the outcome itself.
In this review, we critically appraise the evidence from both
case–control and cohort studies of three risk factors for glioma in
humans: medical radiation, exogenous hormone use and allergy.
The objective is to provide some insight into the difficulty
associated with choosing a study design when studying the risk
factors for glioma. We also propose considerations for applying
scientific weight to the results of case–control studies in this
context.
We searched the Medline–PubMed database on 18 November
2015 using the following search strategy:
Search ((‘Glioma/epidemiology’[Majr] OR (glioma AND epide-
miology))) AND ((((‘Risk Factors’[Mesh]) OR ‘Environment and
Public Health’[Mesh])) OR (Risk OR exposure OR factor* OR
cause*)) Filters: Humans; Meta-Analysis; Review; Systematic Reviews
OR
Search (((((‘Glioma/epidemiology’[Majr] OR (glioma AND
epidemiology))) AND ((((‘Risk Factors’[Mesh]) OR ‘Environment
and Public Health’[Mesh])) OR (Risk OR exposure OR factor* OR
cause*))) AND Humans[Mesh])) AND (((‘Case-Control Studies’
[Mesh]) OR ‘Cohort Studies’[Mesh]) AND Humans[Mesh])
Filters: Humans
This search provided 3018 hits. Using the inclusion criteria
English language paper, adult glioma, case–control study or cohort
study and excluding reviews and/or meta-analyses, overview or
commentary, qualitative methodology, children and adolescents,
genetic exposures and mortality or survival as the outcome, we
identified reports of original studies that included the three selected
risk factors for glioma. Our search was intended to be neither
comprehensive nor systematic for this review. We are aware that
we did not identify some studies, such as those in which the word
‘glioma’ was not in the title, abstract or keywords and those in
which none of the three risk factors was mentioned in the title or
abstract.
From the selected papers, we extracted the characteristics of the
study. We then compared the evidence from studies based on recall
by cases and controls with that from studies with either a case–
control design, with objective (recall-independent) assessment of
exposure or a prospective cohort design.
We selected 30 case–control studies and six cohort studies on the
association between glioma and medical radiation (Preston-Martin
et al, 1989; Neuberger et al, 1991; Schlehofer et al, 1992; Ryan et al,
1992; Zampieri et al, 1994; Ruder et al, 2006; Blettner et al, 2007;
Davis et al, 2011), exogenous hormone use (Huang et al, 2004;
Hatch et al, 2005; Wigertz et al, 2006; Silvera et al, 2006; Benson et al,
2008, 2015; Felini et al, 2009; Michaud et al, 2010; Kabat et al, 2011;
Andersen et al, 2013; Anic et al, 2014; 2015) or allergic diseases
(Cicuttini et al, 1997; Schlehofer et al, 1999, 2011; Wiemels et al,
2002, 2004, 2009; Brenner et al, 2002; Schwartzbaum et al, 2003;
Schoemaker et al, 2006; Wigertz et al, 2007; Scheurer et al, 2008;
Berg-Beckhoff et al, 2009; Il’yasova et al, 2009; 2009; McCarthy et al,
2011; Calboli et al, 2011; Turner et al, 2013; Cahoon et al, 2014).
Table 1 lists the key characteristics of the selected studies.
MEDICAL RADIATION: INFORMATION FROM
PARTICIPANTS ONLY
Ionising radiation is a long-established human carcinogen. Early
cohort studies of patients who received radiation treatment to the
scalp to treat tinea capitis or skin haemangioma during childhood had
an increased risk for glioma, especially after treatment at an early age
(see, e.g., Ron et al, 1988). Early case–control studies suggested
increased risks for glioma after exposure to dental X-rays or X-rays to
the head and neck (Preston-Martin et al, 1989; Neuberger et al, 1991;
Ryan et al, 1992; Schlehofer et al, 1992). In contrast, the German part
of the Interphone study (a multinational interview-based case–control
study on mobile phone use and other risk factors for brain tumours,
acoustic neuroma and salivary gland tumours) indicated that
exposure to any medical ionising radiation significantly reduced the
risk for glioma (OR, 0.63; 95% CI, 0.48–0.83) in a study of 366 glioma
Table 1. ( Continued )
First author, country, year, study design
Case–control study
N glioma cases/N controls; % proxy in case group;
% control participation
Cohort study
N participants; N glioma cases; mean follow-up
Definition of exposure and risk
estimates
Schlehofer, Europe, 2011, case–control 275/528
0% (Nested in cohort)
100% (Nested in cohort)
Serum IgE positive, OR, 0.73 (0.51–1.06)
P for trend of positivity, 0.11
Calboli, USA, 2011, case–control 169/520
0% (Nested in cohort)
100% (Nested in cohort)
Serum IgE above normal, OR, 0.72 (0.51–
1.03)
Turner, Australia, Canada, France, Israel, New
Zealand, 2013, case–control
793/2374
17%
Not provided
Any allergy, OR, 0.73 (0.60–0.88)
Cahoon, USA, 2014, cohort 4 501 578 Mio men,
4383 Glioma cases
Mean follow-up 11.7 years
Any allergy
Latency 42 years, HR, 0.85 (0.72–1.01)
Latency410 years, HR, 0.6 (0.4–0.8)
P for trend of latency, 0.02
Abbreviations: HR¼ hazard ratio; HRT¼ hormone replacement therapy; OC¼oral contraception; OR¼odds ratio; RR¼ relative risk.
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patients (of whom 11% reported information on exposure through
proxies) and 1538 controls (Blettner et al, 2007). Other research
groups have reported a similar protective effect of medical ionising
radiation. In a study in Italy in 1984, of 195 cases and hospital
controls, in which all information was obtained from proxies, the OR
for any diagnostic X-ray was 0.4 (95% CI, 0.1–1.0; Zampieri et al,
1994). In two studies in the USA with 798 and 205 cases (proportions
of proxies not reported), reduced ORs were found after exposure to
full-mouth dental X-rays (OR, 0.75; 95% CI, 0.61–0.92; Ruder et al,
2006) and after one or more yearly dental X-rays or three or more
full-mouth X-rays (0.60; 95% CI, 0.21–1.73 to 0.70; 95% CI,
0.40–1.21; Davis et al, 2011). In personal communications, we have
been informed that medical radiation appears to be protective against
glioma in the entire Interphone data set and that similar results were
obtained in the Gliogene study. Although authors usually appro-
priately discuss the possibility of chance findings, residual confound-
ing and (more importantly) recall bias, use of proxies and selection
bias, data are required to estimate the magnitude and direction of the
potential error; otherwise, most of the conclusions remain speculative.
Most case–control studies continue to rely on self-reported informa-
tion, whereas validation from records of medical radiation or dental
records should be a minimal quality assurance component of studies.
This may be difficult in countries where X-ray machines are available
in all hospitals, big or small, and even in some general practices, so
that it would be virtually impossible to review all the records for false
negatives (that is, examinations not reported by study participants). It
should, however, be feasible on a small sample.
EXOGENOUS HORMONES: SELF-REPORTED USE VERSUS
PRESCRIPTION DATA
Two methods have been used to collect information on exposure in
studies of the relation between use of exogenous hormones and
glioma: self-reported use and prescription data. In a case–control
study in the USA with 619 women with glioma and 650 controls, self-
reported use of hormone replacement therapy (HRT) was associated
with an OR of 0.56 (95% CI, 0.37–0.84; Felini et al, 2009). This result
is in line with those of a number of other case–control studies of self-
reported use of oral contraceptives or HRT, reported separately
(Huang et al, 2004; Hatch et al, 2005; Wigertz et al, 2006; Anic et al,
2014), which did not, however, reach statistical significance. In two
case–control studies nested in population-based registries, with data
on prescriptions collected prospectively and independently of the
study hypothesis, use of HRT did not decrease the risk for glioma,
based on 689 cases (OR, 1.14; 95% CI, 0.93–1.40) and 658 cases (OR,
0.9; 95% CI, 0.8–1.1; Benson et al, 2015 and Andersen et al, 2013).
These results, based on administrative sources, corroborated those of
several very large prospective cohort studies with self-reported data on
use of oral contraceptives or HRT obtained before diagnosis of a
glioma (Silvera et al, 2006; Benson et al, 2008; Michaud et al, 2010;
Kabat et al, 2011). Overall, therefore, relying on self-reported
information on use of exogenous hormones obtained retrospectively
resulted in systematically lower risk estimates than when exposure
was measured prospectively or from prescription data, when no
convincing reductions in risk were observed.
ALLERGY: SAME DIRECTION IN RISK IRRESPECTIVE OF
STUDY DESIGN
The search of an immune factor that may have a role in glioma
aetiology has led to studies of several different definitions of
outcomes—ranging from self-reported allergic conditions or
autoimmune disorders, discharge records of allergic disorders
and use of serum IgE levels as a measure of a hyperactive immune
system. Several case–control studies showed consistently that self-
reported allergic conditions protect against glioma. For example, in
the International Adult Brain Tumour Study, with 1178 glioma
patients (26% of whom reported through proxies) and 2493
population controls, an OR of 0.59 (95% CI, 0.49–0.71) was found
for any self-reported allergy (Schlehofer et al, 1999). Other case–
control studies found similarly reduced ORs; these often had
substantial proportions of proxy informants: 44% (Cicuttini et al,
1997), 24% (Wiemels et al, 2002), 24% (Brenner et al, 2002), 13%
(Wigertz et al, 2007), 4% (Scheurer et al, 2008), 3% (Berg-Beckhoff
et al, 2009), 24% (Wiemels et al, 2009) and 17% (Turner et al,
2013); others did not provide information on the proportion of
proxies (Wiemels et al, 2004; Schoemaker et al, 2006; Il’yasova
et al, 2009; McCarthy et al, 2011). Two Swedish cohorts who self-
reported allergies had non-significantly reduced risks for glioma:
OR, 0.45 (95% CI, 0.19–1.07) among twins born in 1986–1925 but
a nonsignificantly increased risk (OR, 1.09; 95% CI, 0.48–2.48)
among twins born in 1926–1958 (Schwartzbaum et al, 2003). In a
combined analysis of the two twin cohorts and discharge records of
immune-related diseases, including both atopic allergic diseases as
well as autoimmune diseases such as diabetes, rheumatoid arthritis
and so on, as the exposure measure, the risk was reduced but not
significantly (HR, 0.46; 95% CI, 0.14–1.48).
The biological marker immunoglobuline E (IgE) may provide
more specificity and reduce bias stemming from self-report. In a case–
control study from 2004, both self-reported allergies and IgE levels
were reversely associated with gliomas in 258 cases and 289 controls
but, as expected, concordance between the two outcomes was not high
(Wiemels et al, 2004). In a further study from 2009, both self-reported
allergies and IgE levels were reversely associated in 535 cases and 532
controls, but analyses showed that IgE levels obtained in glioma
patients were affected by treatment with telozomide, underscoring the
need for prospectively collected data (Wiemels et al, 2009). A case–
control study nested in the EPIC cohort (Schlehofer et al, 2011) and
thus with prospectively collected data on serum IgE levels reported a
statistically nonsignificant OR of 0.73 (95% CI, 0.51–1.06) based on
275 cases. Another case–control study, nested in four large cohorts in
the USA with 181 cases of glioma, found an almost identical OR of
0.72 (95% CI, 0.51–1.03) for a serum IgE level above normal (Calboli
et al, 2011). A cohort study of hospital discharge records of 4.5 million
men with a mean 12-year follow-up and 4383 events of glioma
showed that any allergy was associated with an HR for glioma of 0.85
(95% CI, 0.72–1.01) with a latency of 42 years and 0.6 (95% CI,
0.4–0.8) with a latency of410 years (Cahoon et al, 2014). In a meta-
analyses of the 14 studies in the international Gliogene case–control
study, published after our literature search, with 4533 cases and 4177
controls ando10% proxies, respiratory allergy was associated with an
OR of 0.72 (95% CI, 0.58–0.90; Amirian et al, 2016a).
Imprecisely defined exposures such as allergic disease probably
affect the validity of the findings of both case–control and cohort
studies. The heterogeneous description of allergy in studies,
different levels of detail in self-reporting on individual allergies
and use of objective measures of serum IgE levels or discharge
records further complicate interpretation of the results. Never-
theless, there is no doubt that most studies of any design, type of
measure and size indicate that allergy or a hyperactive immune
system, through some as yet unidenfied biological mechanisms
might be protective against the development of glioma.
SYNTHESIS OF THE THREE EXAMPLES
In two of our examples, medical radiation and HRT, question-
naire-based case–control studies appeared to show an inverse
association, whereas nested case–control and cohort studies
showed no association. For allergies, the inverse association is
observed irrespective of study design. If the inverse associations
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with medical radiation and HRT use are spurious, possible
explanations are over-reporting by controls, under-reporting by
cases or selection bias in relation to the exposure of interest. Over-
reporting by controls seems unlikely, unless the time between the
reference date (censoring of risk time) and the interview date is
long, when controls may incorrectly remember the dates of
examinations and report those occurring after censoring of the risk
time, as observed in a case–control study on paediatric brain
tumours in Germany (Schu¨z et al, 2001). Selection bias may have
some role, as medical radiation and HRT use are more common
among more affluent people, while participation as a control is
often associated with higher education and income. Under-
reporting is a concern. It might occur because a patient with the
very serious diagnosis of a glioma might view other medical events
as less important and could easily be forgotten in an interview. The
last finding is curious, because, for environmental exposures,
validation studies suggest over-reporting or exaggeration by cases
(for instance, in studies on mobile phone use or occupational
exposure), perhaps because they try to not miss reporting
something they may consider relevant in terms of their cancer
diagnosis. (For discussions on bias in case–control studies on brain
tumours, see, for example, Vrijheid et al, 2006, 2009).
After 30 years of research, we still do not know much about
what causes glioma or protects people from the disease. In the
search for causality, many researchers who are systematically
evaluating the evidence give more weight to that from cohort
studies than from case–control studies (e.g., Cochrane reviews);
others go as far as considering case–control studies useful only for
hypothesis generating because of their retrospective nature (Mann,
2003). In many systematic reviews and meta-analyses in the peer-
reviewed literature; however, there is a tendency to categorise the
evidence from case–control studies with evidence derived from
prospective cohort studies and to give them equal weight. In
studying glioma, we consider it critical that studies based on the
recall of patients with a disease that affects the brain and possibly
cognition should not be given the same weight as nested case–
control studies or cohort studies. In addition to the limitations
inherent in questionnaire-based case–control studies on other
diseases, the risk for recall bias among cases makes it difficult to
draw firm conclusions. Validation studies of recall of exposures by
glioma cases and by controls often show that cases recall the
past differently from controls (Vrijheid et al, 2006, 2009). The
treatment and even the symptoms that arise before treatment, due
to the presence of the tumour, may influence cognitive function,
underscoring these objections. In studies of glioma, the widespread
acceptance of information obtained from the closest relative—a
proxy—adds to the problem of the accuracy of self-reported
information. Going back to our examples, would proxies really
know about the dental X-rays that the patient had during
childhood? Recall bias is an issue not only for the exposure of
interest but also for potential confounders in analyses of the
exposure–disease relationship, as inaccurately measured confoun-
ders obviate appropriate adjustment.
As we have illustrated, studies in which information on
exposure is obtained from sources other than memory for both
cases and controls and in which the information on outcome is
from high quality sources, are more reliable, depending on the
completeness and quality of the data that can be obtained.
The cohort design is not free of problems, but it is less
vulnerable to methodological errors than case–control studies that
rely on the memory of cases and controls. The cohort design is
therefore the preferred type for observational studies. Nevertheless,
because glioma is a rare event, the case–control design may be the
only one possible. During critical appraisal of the evidence derived
from such studies, however, quality indicators should be applied, as
they should for cohort studies. These quality indicators should
address the study population (sampling frame, response rates),
exposure measures (ideally showing results from validations), and
discussion of potential bias affecting the risk estimation.
The superiority of the cohort design and/or access to data
obtained independently of the hypothesis in studies of potential
risk factors for cancer have been illustrated by cohort studies of
various issues, for example, that abortions increase the risk for
breast cancer (Melbye et al, 1997) and that our minds cause cancer
(Johansen, 2012). One may say that when studying i.e. low-dose
radiation and rare outcomes such as gliomas with complicating
problems of recall bias and lack of validation the question cannot
be reduced to just choosing cohort studies over case–control
studies. Cohort studies may actually not be feasible for evaluation
of this exposure. One solution might instead be to extrapolate from
cohort studies with greater ranges of exposure like atomic bomb
survivors or people exposed to nuclear accidents. Poorly conducted
studies give rise to risk, as their outcomes often contribute to
public concern and may shift the focus from the relevant to the
irrelevant, as for instance in the debate about cancer risks and
mobile technologies.
Observational studies on the risk factors for glioma, i.e. reports
from the early case–control studies conducted at the University of
California at San Francisco (USA; see, e.g., Wrensch et al, 2000)
and the University of California at Los Angeles (USA; Preston-
Martin et al, 1989), coordinated by the US National Cancer
Institute (Inskip et al, 2001), the first international case–control
study (Schlehofer et al, 1999), the Interphone study (Cardis et al,
2007) and probably also the most recent Gliogene case–control
study (Malmer et al, 2007), do not provide much evidence on what
causes this devastating cancer. Thus, despite all the resources that
went into those studies, the results did not provide striking
evidence on which to base prevention. Nevertheless, as lifestyle and
environmental factors were studied comprehensively, the results
may suggest that not many of the usual cancer-causing suspects
have an important role in glioma aetiology. This is an important
finding to be acknowledged and suggests that for the identification
of causes novel ideas are needed. Recent reports on genetic risk
factors for glioma suggest that these factors do have a crucial role
in the risk pattern (Amirian et al, 2016b).
The criteria for causality are the strength of the evidence, consis-
tency across populations, specificity, temporality, dose–response and
biological plausibility (Hill, 1965). The temporal criterion should
always be addressed in evaluating the evidence, whereas in case–
control studies, unless secondary data sources can be used, the
information is collected after diagnosis of a disease, that is, the reverse
sequence in temporality. Furthermore, there are major problems in
self-reporting, as cases are aware of having a fatal disease and may
unconsciously change their way of looking at past events. Even
physical measurements should be evaluated for the representativeness
of contemporary measurements of exposure during the aetiologically
relevant period, which might have been decades previously.
On the basis of this review, we recommend that the case–control
design be placed lower in the hierarchy of studies for establishing
cause-and-effect for diseases such as glioma, which pose challenges
for accurate collection of retrospective data. A state-of-the-art
case–control study should as a minimum, be accompanied by
extensive validation of the exposure assessment methods and the
representativeness of the study sample with regard to the exposures
of interest. Otherwise, such studies cannot be termed ‘hypothesis
testing’ but only ‘hypothesis generating’. We consider that this
holds true for all questionnaire-based case–control studies on all
cancers and chronic diseases, although perhaps not to the same
extent for each exposure–outcome combination. For example,
case–control studies clearly linked smoking with lung cancer in the
1950s, prenatal radiation to the fetus with childhood leukemia in
the late 1950s/early 1960s, postmenopausal oestrogens with uterine
endometrial cancer in the 1960s and diethylstilbestrol with vaginal
adenocarcinoma in 1971. Almost all known risk factors for breast
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cancer were identified in case–control studies and much of the
evidence that identified smoking and types of tobacco as the cause
of about 50% of bladder cancer was based on case–control studies.
However, this list does not include risk factors for glioma and these
earlier studies, in some cases, showed risk estimates robust to such
a degree that even potential bias could not hamper the associations
observed.
We hope that the examples we have provided underscore our
points and that our recommendation will be taken into account in
ranking the evidence obtained from case–control studies and also
in the design of such studies in cancer epidemiology.
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